U.S. FDA Approves Blue Earth Diagnostics' POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer
- POSLUMA will be commercially available in the United States in early June 2023 - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative